PMID: 1928026Sep 1, 1991Paper

Substance abuse and schizophrenia: impediments to optimal care

The American Journal of Drug and Alcohol Abuse
I M SalloumD C Daley

Abstract

With lifetime prevalence estimates of substance abuse among schizophrenics as high as 47.01%, there is an increasing awareness of the importance of this dual diagnosis and the global deficiencies in our knowledge about this comorbid condition. Patients with substance abuse disorders and schizophrenia are problematic from a clinical, economic, and health care systems perspective. The lack of systematic research into phenomenology, etiology, and treatment approaches (both psychotherapeutic and psychopharmacologic) has hindered the development of an adequate strategy to care for the needs of these patients. Thus, these patients place a significant burden on the mental health delivery system through chronic disability, social dysfunction, frequent rehospitalizations, and poor overall treatment compliance. The authors critically review the contemporary literature relevant to concurrent substance abuse and schizophrenia, highlight major deficiencies in our knowledge, and call for research to reduce the individual, economic, and social costs of this condition.

References

Oct 1, 1978·The American Journal of Psychiatry·D A Treffert
Dec 13, 1979·The New England Journal of Medicine·A T Mc LellanC P O'Brien
Jul 1, 1975·Journal of Studies on Alcohol·E X Freed
Oct 1, 1979·Drugs·M LinnoilaB S Kitchell
Sep 1, 1979·Hospital & Community Psychiatry·R Stern, K Minkoff
Jan 1, 1977·The American Journal of Drug and Alcohol Abuse·R C HallS K Stickney
May 1, 1978·Psychological Medicine·J Cutting
Nov 1, 1978·Journal of Studies on Alcohol·T Deiker, H E Chambers
Mar 1, 1976·Archives of General Psychiatry·D S Janowsky, J M Davis
Aug 1, 1976·The British Journal of Psychiatry : the Journal of Mental Science·C E Vaughn, J P Leff
Nov 21, 1990·JAMA : the Journal of the American Medical Association·D A RegierF K Goodwin
Jan 1, 1989·British Journal of Addiction·I B Glass
Jan 1, 1989·Comprehensive Psychiatry·R CastenedaH Franco
Jun 1, 1989·Acta Psychiatrica Scandinavica·A E PulverJ A McGrath
May 1, 1985·Clinical Pharmacokinetics·E A LaneM Linnoila
Sep 1, 1985·The American Journal of Psychiatry·D A BrizerR B Millman
Jan 1, 1989·Journal of Studies on Alcohol·A M Toland, H B Moss
Jan 1, 1986·Social Work in Health Care·P Solomon, J M Davis
Jul 1, 1986·The American Journal of Psychiatry·L KofoedR M Atkinson
Nov 1, 1988·Archives of General Psychiatry·H E RossT Germanson
Jul 1, 1987·British Heart Journal·A L Muir
Aug 1, 1987·Journal of Clinical Pharmacology·A J Giannini, W Billett
Nov 1, 1987·The Journal of Nervous and Mental Disease·F R Schneier, S G Siris
Jun 1, 1987·Archives of General Psychiatry·B J RounsavilleR E Meyer
May 1, 1987·Drug and Alcohol Dependence·A Blankfield
May 1, 1987·Hospital & Community Psychiatry·D J Safer
Oct 1, 1987·The American Journal of Psychiatry·D J Hellerstein, B Meehan
Aug 1, 1986·Archives of General Psychiatry·B J RounsavilleH D Kleber
Apr 1, 1986·The British Journal of Psychiatry : the Journal of Mental Science·M W Bernadt, R M Murray
Apr 1, 1985·The American Journal of Psychiatry·D G SpikerP H Soloff
Nov 1, 1985·The American Journal of Psychiatry·E J Khantzian
Feb 1, 1986·Psychological Medicine·S W TurnerJ R Brett-Jones
Nov 1, 1985·Archives of General Psychiatry·M N HesselbrockJ J Keener
Jul 1, 1985·The British Journal of Psychiatry : the Journal of Mental Science·K S Kendler
Aug 1, 1974·Psychological Medicine·W R BreakeyP R McHugh
Sep 1, 1972·The British Journal of Addiction to Alcohol and Other Drugs·K Davison, C H Wilson
Feb 1, 1972·Archives of General Psychiatry·J D GriffithJ A Oates
Dec 1, 1972·The American Journal of Psychiatry·D A SchwartzJ M Miner
Jul 1, 1973·Archives of General Psychiatry·D S Bell
Aug 1, 1973·The Journal of Nervous and Mental Disease·F BaekelandT J Shanahan
Feb 1, 1974·Canadian Psychiatric Association Journal·M Tyndel
Jan 1, 1974·The British Journal of Psychiatry : the Journal of Mental Science·B G Young
Dec 1, 1970·The American Journal of Medicine·E RubinC S Lieber
Jan 1, 1980·Schizophrenia Bulletin·L R Mosher, S J Keith
Feb 1, 1980·Canadian Journal of Psychiatry. Revue Canadienne De Psychiatrie·F G Surawicz
Feb 1, 1984·Acta Psychiatrica Scandinavica·P Knudsen, T Vilmar

Citations

Feb 1, 1997·Social Psychiatry and Psychiatric Epidemiology·C NageotteP L Camp
Jul 1, 1995·Psychopharmacology·A SmithD C Roberts
Oct 26, 2005·Social Psychiatry and Psychiatric Epidemiology·Michael T ComptonNadine J Kaslow
May 1, 1996·Schizophrenia Research·C D SwoffordL B Inderbitzin
May 1, 1996·Schizophrenia Research·B KirkpatrickT H McGlashan
Feb 16, 1999·Schizophrenia Research·G Scheller-GilkeyF W Brown
Apr 6, 1999·Schizophrenia Research·J H KrystalI L Petrakis
Jan 1, 2000·International Journal of Psychiatry in Clinical Practice·N Tarrier, J Bobes
May 23, 2007·Journal of Psychiatric and Mental Health Nursing·L Coombes, A Wratten
Jul 1, 2006·Revista brasileira de psiquiatria : orgão oficial da Associação Brasileira de Psiquiatria, Asociación Psiquiátrica de la América Latina·Marcos ZaleskiBrazilian Association of Studies on Alcohol and Other Drugs

Related Concepts

Trending Feeds

COVID-19

Coronaviruses encompass a large family of viruses that cause the common cold as well as more serious diseases, such as the ongoing outbreak of coronavirus disease 2019 (COVID-19; formally known as 2019-nCoV). Coronaviruses can spread from animals to humans; symptoms include fever, cough, shortness of breath, and breathing difficulties; in more severe cases, infection can lead to death. This feed covers recent research on COVID-19.

STING Receptor Agonists

Stimulator of IFN genes (STING) are a group of transmembrane proteins that are involved in the induction of type I interferon that is important in the innate immune response. The stimulation of STING has been an active area of research in the treatment of cancer and infectious diseases. Here is the latest research on STING receptor agonists.

Chronic Fatigue Syndrome

Chronic fatigue syndrome is a disease characterized by unexplained disabling fatigue; the pathology of which is incompletely understood. Discover the latest research on chronic fatigue syndrome here.

Hereditary Sensory Autonomic Neuropathy

Hereditary Sensory Autonomic Neuropathies are a group of inherited neurodegenerative disorders characterized clinically by loss of sensation and autonomic dysfunction. Here is the latest research on these neuropathies.

Glut1 Deficiency

Glut1 deficiency, an autosomal dominant, genetic metabolic disorder associated with a deficiency of GLUT1, the protein that transports glucose across the blood brain barrier, is characterized by mental and motor developmental delays and infantile seizures. Follow the latest research on Glut1 deficiency with this feed.

Regulation of Vocal-Motor Plasticity

Dopaminergic projections to the basal ganglia and nucleus accumbens shape the learning and plasticity of motivated behaviors across species including the regulation of vocal-motor plasticity and performance in songbirds. Discover the latest research on the regulation of vocal-motor plasticity here.

Neural Activity: Imaging

Imaging of neural activity in vivo has developed rapidly recently with the advancement of fluorescence microscopy, including new applications using miniaturized microscopes (miniscopes). This feed follows the progress in this growing field.

Nodding Syndrome

Nodding Syndrome is a neurological and epileptiform disorder characterized by psychomotor, mental, and growth retardation. Discover the latest research on Nodding Syndrome here.

LRRK2 & Microtubules

Mutations in the LRRK2 gene are risk-factors for developing Parkinson’s disease (PD). LRRK2 mutations in PD have been shown to enhance its association with microtubules. Here is the latest research.